News

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024

The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ETCORAL GABLES, Fla.,…

1 month ago

Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the…

1 month ago

Reflect Scientific Inc. Secures $225,000 Order for Cutting-Edge Freezer Systems

OREM, Utah, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Reflect Scientific Inc. (OTCQB: RSCF), a leading innovator in cryogenic technology, announced…

1 month ago

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9…

1 month ago

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative…

1 month ago

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now…

1 month ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS.REC-3964 represents a novel, non-antibiotic approach with a unique mechanism…

1 month ago

Annovis to Highlight Buntanetap’s Alzheimer’s Research Progress with Presentations at CTAD 2024

MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"),…

1 month ago

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing…

1 month ago